Aricept Complexed with Acetylcholinesterase: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 2: | Line 2: | ||
[[Image:E2020_interactins_in_AChE_gorge.jpg|left|250px]]<br /> | [[Image:E2020_interactins_in_AChE_gorge.jpg|left|250px]]<br /> | ||
'''3D structure of anti-Alzheimer's drug, Aricept, complexed with acetylcholinesterase''' | '''3D structure of anti-Alzheimer's drug, Aricept, complexed with acetylcholinesterase''' | ||
(see also [[AChE | (see also [[AChE inhibitors and substrates]]) | ||
==Background== | ==Background== | ||
Several cholinesterase inhibitors are either being utilized for symptomatic treatment of Alzheimer's disease or are in advanced clinical trials. '''E2020''', marketed as '''Aricept''', is a member of a large family of N-benzylpiperidine-based [[acetylcholinesterase]] (AChE) inhibitors, developed, synthesized and evaluated by the Eisai Company in Japan. These inhibitors were designed on the basis of QSAR studies prior to elucidation of the 3D structure of ''Torpedo californica'' AChE (''Tc''AChE) ([[1ea5]]). It significantly enhances performance in animal models of cholinergic hypofunction and has a high affinity for AChE, binding to both electric eel and mouse AChE in the nanomolar range. | Several cholinesterase inhibitors are either being utilized for symptomatic treatment of Alzheimer's disease or are in advanced clinical trials. '''E2020''', marketed as '''Aricept''', is a member of a large family of N-benzylpiperidine-based [[acetylcholinesterase]] (AChE) inhibitors, developed, synthesized and evaluated by the Eisai Company in Japan. These inhibitors were designed on the basis of QSAR studies prior to elucidation of the 3D structure of ''Torpedo californica'' AChE (''Tc''AChE) ([[1ea5]]). It significantly enhances performance in animal models of cholinergic hypofunction and has a high affinity for AChE, binding to both electric eel and mouse AChE in the nanomolar range. | ||
| Line 20: | Line 20: | ||
==Additional Resources== | ==Additional Resources== | ||
For additional information, see: [[Alzheimer's Disease]]<br /> | For additional information, see: [[Alzheimer's Disease]]<br /> | ||
<br /> | <br /> | ||
</StructureSection> | </StructureSection> | ||
| Line 41: | Line 41: | ||
[[vi:Aricept_Complexed_with_Acetylcholinesterase (Vietnamese)]] | [[vi:Aricept_Complexed_with_Acetylcholinesterase (Vietnamese)]] | ||
[[tr:Aricept_Complexed_with_Acetylcholinesterase (Turkish)]] | [[tr:Aricept_Complexed_with_Acetylcholinesterase (Turkish)]] | ||
[[hi:Aricept Complexed with_Acetylcholinesterase (Hindi)]]<br /> | |||
[[Category: Acetylcholinesterase]] | [[Category: Acetylcholinesterase]] | ||